US Prostate Cancer Conference (USPCC)

Oliver Sartor, MD, discusses the use of PSMA PET and radioligand therapy in prostate cancer.

Oliver Sartor, MD, discusses ongoing prostate cancer research, highlighting the importance of considering patient quality of life.

Jeremie Calais, MD, PhD, discusses controversies and unresolved questions in the treatment of patients with prostate cancer.

Tian Zhang, MD, MHS, discusses areas of ongoing debate regarding prostate cancer management.

Neeraj Agarwal, FASCO, MD, discusses quality of life considerations for patients with prostate cancer.

Neal Shore, MD, FACS, discusses findings from clinical trials in patients with prostate cancer who experience biochemical recurrence.

Maha Hussain, MD, FACP, FASCO, discusses clinical trials evaluating therapeutics for patients with metastatic castrate-resistant prostate cancer.

Phillip J. Koo, MD, discusses ongoing areas of technological and therapeutic advancements within the prostate cancer landscape.

Matthew Rettig, MD, discusses emerging treatment options for patients with stage IV metastatic prostate cancer and highlights key data from clinical trials in the space.

Andrei H. Iagaru, MD, discusses molecular imaging and the use of prostate-specific membrane antigen PET scans in prostate cancer and highlights other key presentations from the 2023 Prost8 Cancer Conference.

Tian Zhang, MD, MHS, discusses findings with single-agent PARP inhibitors within homologous recombination repair–deficient metastatic castration-resistant prostate cancer and describes how these advances pave the way for combining PARP inhibitors with hormonal therapies.

Phillip J. Koo, MD, highlights insights garnered from prostate cancer experts on topics such as radioligands and modern radiopharmaceuticals, which, along with artificial intelligence, have the potential to revolutionize the field.

Tian Zhang, MD, MHS, discusses the use of PARP inhibitor–based combinations in patients with metastatic castration-resistant prostate cancer.

Michael S. Cookson, MD, MMHC, explains how discrepancies in defining biochemical recurrence are sparking a conversation about creating more consistent definitions that could allow for more widely applicable standards of care in prostate cancer .